Meadow Creek Investment Management’s Anika Therapeutics ANIK Stock Holding History

Meadow Creek Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$70K	Buy	+1,280	New	+$65.7K	﹤0.01%	1243

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Meadow Creek Investment Management's ANIK Position: Q3 2019 in Review

Meadow Creek Investment Management opened a new position in Anika Therapeutics (ANIK) in Q3 2019: 1,280 shares worth $70K. The stake represents ﹤0.01% of the portfolio and ranks #1243 among its holdings.

194 funds tracked by Wall St. Rank hold ANIK as of Q3 2019.

Meadow Creek Investment Management held 1,280 shares of Anika Therapeutics worth $70K as of Q3 2019.
Anika Therapeutics was a new Meadow Creek Investment Management position in Q3 2019.
Anika Therapeutics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1243 holding.
194 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.